high mobility group box 3 pseudogene 13Genealiases: []
Q-omics provides the consensus-scored HMGB3P13 profile across patient tissues and cancer cell-line models. HMGB3P13 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HMGB3P13 is differentially expressed in 5, with the highest sampling consensus in UCEC. Additionally, HMGB3P13 RNA expression shows 8,084 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, UCEC, and THYM as cancer lineages where HMGB3P13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGB3P13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGB3P13 survival associations across molecular data types. HMGB3P13 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGB3P13 RNA expression–survival associations across cancer types. High HMGB3P13 expression shows unfavorable associations in ACC, KICH, UCS, UVM and PAAD, but favorable associations in LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HMGB3P13 RNA expression.
This table summarizes HMGB3P13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for HMGB3P13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGB3P13 shows higher tumor expression in UCEC, LUAD, HNSC, LIHC and PRAD. The UCEC box plot shows higher HMGB3P13 RNA expression in tumor versus normal tissue (log2 FC = +0.235, t-test p = .034).
This table shows molecular features associated with HMGB3P13 in patient tissues and cancer cell lines. In patient samples, HMGB3P13 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
